Targeted Drugs, PADN, and Transcatheter Closure for Atrial Septal Defect-Associated Pulmonary Hypertension.

Dandan Chen, Dawei Lin, Lei Zhang, Xiaochun Zhang, Daxin Zhou, Junbo Ge, Lihua Guan, Wenzhi Pan

Abstract readCase Reports

In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dandan ChenDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Dawei LinDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Lei ZhangDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Xiaochun ZhangDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Daxin ZhouDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Junbo GeDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Lihua GuanDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.

Wenzhi PanDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China. Electronic address: peden@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted drug therapy and subsequent transcatheter closure are effective in treating atrial septal defects in patients with severe pulmonary arterial hypertension. Nevertheless, despite sufficient pharmacological therapy, many patients do not satisfy the hemodynamic criteria for transcatheter closure under the current guidelines. Here, we report 2 patients with atrial septal defect complicated by pulmonary arterial hypertension, in which successful transcatheter occlusion was achieved through prodromal targeted drug therapy combined with pulmonary artery denervation ablation (PADN). PADN can improve hemodynamic variables in patients who receive adequate targeted drug therapy, which enables them to meet the conditions for performing the occlusion procedure. These cases suggest that PADN is a novel therapeutic approach for patients with congenital heart disease who are in the gray zone of pulmonary arterial hypertension.

Indexed as

atrial septal defectpulmonary artery denervation ablationpulmonary hypertension

Identifiers

PMID41313291

DOI10.1016/j.jaccas.2025.106116

PMCPMC12926062

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.